Seven months ago, independent clinical trial observers peeked at interim data for Praxis Precision Medicines’ essential tremor drug and recommended stopping the Phase 3 studies. Praxis kept going. On ...

BOSTON - Praxis Precision Medicines Inc. (NASDAQ: PRAX) announced that the Independent Data Monitoring Committee (IDMC) has recommended halting Study 1 of the Essential3 program, which is evaluating ...

Praxis Precision Medicines remains a Hold as valuation now reflects high expectations for ulixacaltamide and its epilepsy ...

Tuesday, Praxis Precision Medicines Inc . (NASDAQ:PRAX) shares received a boost as Truist Securities increased its price target for the company to $175 from $150, while maintaining a Buy rating. The ...

Shares of Praxis Precision MedicinesPRAX skyrocketed more than 180% Thursday, hitting a three-year high, on "groundbreaking" test results for an essential tremor treatment. Praxis stock catapulted 183 ...

The last time I spoke about Praxis Precision Medicines, Inc. (PRAX), it was in a Seeking Alpha article entitled "Praxis: Still A 'Hold' Despite Interim Analysis Setback Of Ulixacaltamide." At that ...

Praxis Precision Medicines, Inc. announced significant progress in its clinical pipeline, projecting six major study readouts across four programs in the next 12 months. The company plans to initiate ...

BOSTON, May 09, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...

Praxis Precision Medicines is converting its EMBRAVE3 study of elsunersen for children suffering from a developmental disease into a single-arm study after meeting with the Food and Drug ...

BOSTON, June 06, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...